Anti-HIV dual specificity antibodies and methods of HIV treatment

Patent metadata

Field	Value
Publication number	US-11059882-B2
Application number	US-201815968090-A
Country	US
Kind code	B2
Filing date	May 1, 2018
Priority date	Jul 25, 2013
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

Dual variable domain immunoglobulins (DVD Igs) are provided capable of tetravalent binding to bispecific sites of the human immunodeficiency virus (HIV). The DVD Igs may be asymmetric and may have more variable domains on either the light chain or the heavy chain of the Igs. The DVD Igs may have specificity for gp41 and gp120. Therapies are provided using DVD Igs to neutralize HIV viral loads.

First claim

What is claimed is:

1. A pharmaceutical composition comprising an asymmetric double variable domain (DVD) antibody comprising at least one immunoglobulin heavy chain light chain cross-linked pair, wherein the immunoglobulin heavy chain-light chain pair comprises a first variable domain having binding affinity for an epitope of an HIV gp41 polypeptide and further comprising a second variable domain having binding affinity for an epitope of an HIV gp120 polypeptide, wherein the second variable domain is linked by a linker peptide to the first variable domain of the immunoglobulin heavy chain or immunoglobulin light chain, but is not linked to the first variable domains of both the immunoglobulin heavy chain and the immunoglobulin light chain.

2. The pharmaceutical composition of claim 1 , wherein the second variable domain having binding affinity for an epitope of an HIV gp120 polypeptide is a CD4 polypeptide or a fragment thereof.

3. The pharmaceutical composition of claim 1 , wherein the first peptide domain having binding affinity for an epitope of an HIV gp41 polypeptide is the immunoglobulin variable region of monoclonal antibody 7B2.

4. The pharmaceutical composition of claim 1 , wherein, in a heavy chain-light chain pair, the heavy chain comprises a first variable domain linked to a second variable domain and the light chain comprises a first variable domain but not a second variable domain.

5. The pharmaceutical composition of claim 1 , wherein in a heavy chain-light chain pair, the light chain comprises a first variable domain linked to a second variable domain and the heavy chain comprises a first variable domain but not a second variable domain.

6. The pharmaceutical composition of claim 1 , wherein the linker peptide comprises a helical core.

7. The pharmaceutical composition of claim 1 , wherein the linker peptide comprises a helical core having a flexible domain at both the N-terminus and the C-terminus thereof.

8. The pharmaceutical composition of claim 1 , wherein the heavy chain has an amino acid sequence selected from the group consisting of: SEQ ID Nos.: 3, 4, and 8, and wherein the light chain has an amino acid sequence selected from the group consisting of: SEQ ID Nos.: 5, 6, and 7.

9. The pharmaceutical composition of claim 1 , wherein the cross-linked heavy and light chains have cross-linked amino acid sequences selected from the group consisting of: SEQ ID Nos.: 3 and 5, 4 and 6, 8 and 5, 3 and 7, 8 and 6, and 4 and 7.

10. The pharmaceutical composition of claim 1 , wherein the cross-linked heavy and light chains have amino acid sequences selected from the group consisting of: SEQ ID Nos.: 3 and 5, 4 and 6, 8 and 5, 3 and 7, 8 and 6, and 4 and 7.

11. The pharmaceutical composition of claim 1 , wherein the linker peptide has an amino acid sequence according to SEQ ID NO: 9.

12. The pharmaceutical composition of claim 1 , wherein the linker peptide has an amino acid sequence according to SEQ ID NO: 10.

13. The pharmaceutical composition of claim 1 , wherein the artificial immunoglobulin is admixed with a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 1 , wherein each of the heavy and the light chains is an expression product from an expression vector.

15. The pharmaceutical composition of claim 14 , wherein at least one of the heavy and the light chain expression products from the expression vector has an N-terminal leader sequence attached thereto.

16. A method of reducing the infectivity of an HIV by contacting said virus with the pharmaceutical composition according to any of claims 1 - 15 .

17. A method of reducing the viability of an HIV-infected cell by the steps of:
contacting a cell infected with a strain of HIV with an asymmetric DVD-antibody of the pharmaceutical composition according to any of claims 1 - 15 , whereby said DVD-antibody binds to a cell surface polypeptide of the infected cell forming a cell-DVD-antibody complex; and
contacting said cell-DVD-antibody complex with a cytotoxic agent capable of specifically recognizing the cell-bound DVD-antibody, thereby delivering the cytotoxic agent to the HIV-infected cell and reducing the viability of an HIV-infected cell.

18. The method of claim 17 , wherein the cytotoxic agent is an engineered anti-immunoglobulin IgG antibody conjugated to a cytotoxic polypeptide, wherein the engineered anti-immunoglobulin IgG antibody specifically binds to a constant region of the asymmetric DVD-antibody.

19. The method of claim 17 , wherein the cytotoxic polypeptide is a ricin A chain.

Assignees

• Univ Louisiana State

Inventors

• Pincus Seth
• Craig Ryan

Classifications

• C07K16/1145 Primary

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K2317/70

  characterized by effect upon binding to a cell or to an antigen · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title